Boston Scientific CorporationBSXNYSE
Loading
EBITDA Over TimeStrong
Percentile Rank93
3Y CAGR+10.8%
5Y CAGR+19.8%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+10.8%/yr
vs +1.5%/yr prior
5Y CAGR
+19.8%/yr
Recent deceleration
Acceleration
+9.4pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $3.73B | -5.2% |
| 2024 | $3.94B | +14.0% |
| 2023 | $3.45B | +26.0% |
| 2022 | $2.74B | +8.9% |
| 2021 | $2.52B | +66.6% |
| 2020 | $1.51B | -31.6% |
| 2019 | $2.21B | -14.5% |
| 2018 | $2.58B | +28.8% |
| 2017 | $2.01B | +63.7% |
| 2016 | $1.23B | - |